Therapy Areas: Inflammatory Diseases
Eli Lilly agrees to acquire Ventyx Biosciences
8 January 2026 - Pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Wednesday that it has signed a definitive agreement to acquire Ventyx Biosciences Inc (Nasdaq:VTYX), a clinical-st...
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
7 January 2026 - Clinical-stage biotechnology company Bambusa Therapeutics Inc announced on Tuesday that the first patient has been dosed in the Phase Ib clinical trial of BBT002, a novel platform-in-...
Hoth Therapeutics files two US provisional patent applications to establish oncology-focused dermatology platform
5 January 2026 - Hoth Therapeutics (NASDAQ:HOTH), a US-based clinical-stage biopharmaceutical company focused on developing innovative therapies for underserved medical needs, announced on Friday an e...
Elanco Animal Health's Befrena (tirnovetmab) receives USDA approval for canine dermatitis
2 January 2026 - Animal health specialist Elanco Animal Health Incorporated (NYSE:ELAN) announced on Wednesday that it has received approval from the US Department of Agriculture (USDA) for Befrena (t...
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
23 December 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) on Tuesday announced approval from J...
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
23 December 2025 - Clinical-stage immunotherapeutics company Aqualung Therapeutics announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for a Phase 2a study...